Clinical Case Study EDW Emily Walker

Sales Associate at Orange Theory Fitness
Dec. 7, 2016
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
Clinical Case Study EDW Emily Walker
1 of 29

More Related Content

What's hot

Case Study 2Case Study 2
Case Study 2Sarah Allaben
Nutrition 2014Nutrition 2014
Nutrition 2014Lama K Banna
Nutritional support and fluid therapy in surgeryNutritional support and fluid therapy in surgery
Nutritional support and fluid therapy in surgeryAjai Sasidhar
Case study  hypertension presentation showCase study  hypertension presentation show
Case study hypertension presentation showKern Rocke
Mellss surgery yr3 nutritional and fluid therapyMellss surgery yr3 nutritional and fluid therapy
Mellss surgery yr3 nutritional and fluid therapynur amalina aminuddin baki
Cystic Fibrosis Nutritional Case Study PresentationCystic Fibrosis Nutritional Case Study Presentation
Cystic Fibrosis Nutritional Case Study PresentationMary Rodavich

Viewers also liked

Case presentation controversies in CardiomyopathyCase presentation controversies in Cardiomyopathy
Case presentation controversies in Cardiomyopathydrucsamal
Clinical Case - Suractant Deficiency DisorderClinical Case - Suractant Deficiency Disorder
Clinical Case - Suractant Deficiency DisorderLana Chagas
Addressing Key Selection CriteriaAddressing Key Selection Criteria
Addressing Key Selection CriteriaCareer Development Centre, La Trobe University
Case Study  Hypertrophic CardiomyopathyCase Study  Hypertrophic Cardiomyopathy
Case Study Hypertrophic Cardiomyopathyjmlafroscia
Hiv Case Study PresentationHiv Case Study Presentation
Hiv Case Study Presentationjeska62
Failure to Thrive: A Case StudyFailure to Thrive: A Case Study
Failure to Thrive: A Case StudyEmily Todhunter

Similar to Clinical Case Study EDW Emily Walker

6032916 (1).ppt6032916 (1).ppt
6032916 (1).pptMhmwdFthy
Anorexia Nervosa Case StudyAnorexia Nervosa Case Study
Anorexia Nervosa Case StudyRoanna Martin
Nutrition, Exercise, and Renal DiseaseNutrition, Exercise, and Renal Disease
Nutrition, Exercise, and Renal Diseasemilfamln
Congestive Heart Failure Case StudyCongestive Heart Failure Case Study
Congestive Heart Failure Case StudyMegan Smith
CDK case study pdf nov 13CDK case study pdf nov 13
CDK case study pdf nov 13Carolina chaves
Fatigue, weakness & weight lossFatigue, weakness & weight loss
Fatigue, weakness & weight losszhenya krapivinsky

Clinical Case Study EDW Emily Walker

Editor's Notes

  1. Cardiomyopathy refers to diseases of the heart muscle. These diseases have many causes, signs and symptoms, and treatments. In cardiomyopathy, the heart muscle becomes enlarged, thick, or rigid. In rare cases, the muscle tissue in the heart is replaced with scar tissue. As cardiomyopathy worsens, the heart becomes weaker. It's less able to pump blood through the body and maintain a normal electrical rhythm. This can lead to heart failure or irregular heartbeats called arrhythmias. In turn, heart failure can cause fluid to build up in the lungs, ankles, feet, legs, or abdomen. ICD: implantable cardioverter defibbrillator: electronic device that constantly monitors heart rhythm when it detects a very fast abnormal heart rhythm it delivers energy to the heart muscle Pt is well known to EDW due to frequent hospital admissions, and
  2. Information from physicians note at admission
  3. Milirone: vasodilator short term for advanced heart failure Implantable cardioverter defribllator: useful in preventing sudden death from ventricular tachycardia
  4. The disease often starts in the left ventricle, the heart's main pumping chamber. The heart muscle begins to dilate (stretch and become thinner). This causes the inside of the chamber to enlarge. The problem often spreads to the right ventricle and then to the atria as the disease gets worse Bodybuilders have used gamma-hydroxybutyrate, a potent secretagogue of growth hormone, to promote muscle development. Idiopathic, genetic, diabetes, alcohol, drugs,
  5. In LV systolic dysfunction, the body activates several neurohormonal pathways to increase circulating blood volume. The sympathetic nervous system increases heart rate and contractility, causes arteriolar vasoconstriction in nonessential vascular beds, and stimulates secretion of renin from the juxtaglomerular apparatus of the kidney. Unfortunately, catecholamines aggravate ischemia, potentiate arrhythmias, promote cardiac remodeling, and are directly toxic to myocytes. Stimulation of the renin-angiotensin system as a result of increased sympathetic stimulation and decreased renal perfusion results in further arteriolar vasoconstriction, sodium and water retention, and release of aldosterone. An increased aldosterone level, in turn, leads to sodium and water retention, endothelial dysfunction, and organ fibrosis. In heart failure, baroreceptor and osmotic stimuli lead to vasopressin release from the hypothalamus, causing reabsorption of water in the renal collecting duct. Although these neurohormonal pathways initially are compensatory and beneficial, eventually they are deleterious, and neurohormonal modulation is the basis for modern medical treatment of heart failure. In contrast, natriuretic peptides are hormones released by secretory granules in cardiac myocytes in response to myocardial stretching. They have a beneficial influence in heart failure, including systemic and pulmonary vasodilation, possible enhancement of sodium and water excretion, and suppression of other neurohormones. With continuous neurohormonal stimulation, the left ventricle undergoes remodeling consisting of LV dilation and hypertrophy, such that stroke volume is increased without an actual increase in EF. This is achieved by myocyte hypertrophy and elongation. LV chamber dilation causes increased wall tension, worsens subendocardial myocardial perfusion, and can provoke ischemia in patients with coronary atherosclerosis. Furthermore, dilation of the LV chamber can cause mitral annular dilatation and functional mitral regurgitation, leading to pulmonary congestion. Indicators of poor cardiac prognosis include renal dysfunction, cachexia, valvular regurgitation, ventricular arrhythmias, higher NYHA heart failure class, lower LV ejection fraction (LVEF), high catecholamine and B-type natriuretic peptide (BNP) levels, low serum sodium level, hypocholesterolemia, and marked LV dilation. Patients with combined systolic and diastolic LV dysfunction also have a worse prognosis than patients with either in isolation.3 Indicators of poor prognosis presents with: Renal dysfunction, high BNP levels,
  6. Two year survival if NHYA Class IV [symptomatic at rest] is 13-40% LVAD placement necessary this hospital admission.
  7. Swan Ganz cathetar placement to monitor hemodynamics and adjust inotropes and diuretics Extremely low cardiac output index of 1.1 L /min An inotrope is an agent that alters the force or energy of muscular contractions. Negatively inotropic agents weaken the force of muscular contractions. Positively inotropic agents increase the strength of muscular contraction
  8. Not a transplant candidate at this time due to weight of 350 pounds. No. HeartMate II is not an artificial heart, nor is it a heart replacement. The patient’s native heart is not removed. HeartMate II attaches to the heart and is designed to assist —or take over—the pumping function of the patient’s left ventricle—the main pumping chamber of the heart. HeartMate II is designed to last for years. HeartMate II recipients have been living with a single device for over 8 years now, and over 700 recipients have been supported more than 5 years. HeartMate II is designed to work for a long time. The Pocket Controller is always checking the system operation. It will let you know if there is a problem, and you will learn what to look for, too. The system also will be checked during your regular medical visits. Having extra batteries charged and ready will keep you prepared for a power outage. You will also receive a power module, which can be moved to another location with power or plugged into a car. In an emergency, your Pocket Controller also has at least an additional 15 minutes of backup battery power.
  9. Power module: supplies main power provides 30 minutes back up power, electrical interface between system controller and display module Batteries: 6-10 hours of support, up to 4 hours to recharge for fully charged battery Emergency: 12 hours of support, event of a power outage
  10. Dobatamine: Blood pressure support It can treat heart failure and help the heart pump blood
  11. INR: monitor effectiveness of warfarin